These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28198434)

  • 21. Spliceosome Mutations in Uveal Melanoma.
    Nguyen JQN; Drabarek W; Yavuzyigitoglu S; Medico Salsench E; Verdijk RM; Naus NC; de Klein A; Kiliç E; Brosens E
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.
    Paolella BR; Gibson WJ; Urbanski LM; Alberta JA; Zack TI; Bandopadhayay P; Nichols CA; Agarwalla PK; Brown MS; Lamothe R; Yu Y; Choi PS; Obeng EA; Heckl D; Wei G; Wang B; Tsherniak A; Vazquez F; Weir BA; Root DE; Cowley GS; Buhrlage SJ; Stiles CD; Ebert BL; Hahn WC; Reed R; Beroukhim R
    Elife; 2017 Feb; 6():. PubMed ID: 28177281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
    Spinello A; Borišek J; Malcovati L; Magistrato A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages.
    Effenberger KA; Urabe VK; Prichard BE; Ghosh AK; Jurica MS
    RNA; 2016 Mar; 22(3):350-9. PubMed ID: 26742993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin.
    Murthy T; Bluemn T; Gupta AK; Reimer M; Rao S; Pillai MM; Minella AC
    J Biol Chem; 2018 Jun; 293(26):10220-10234. PubMed ID: 29764937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules.
    Raja VJ; Lim KH; Leong CO; Kam TS; Bradshaw TD
    Invest New Drugs; 2014 Oct; 32(5):838-50. PubMed ID: 24927857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
    Zhang D; Meng F
    ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AI-assisted proofreading of RNA splicing.
    Guerra-Moreno Á; Valcárcel J
    Genes Dev; 2023 Dec; 37(21-24):945-947. PubMed ID: 38092520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.
    Sciarrillo R; Terrana F; Comandatore A; Supadmanaba IGP; Wang B; Hassouni BE; Mantini G; Jansen G; Avan A; Carbone D; Diana P; Peters GJ; Morelli L; Cloos J; Assaraf YG; Giovannetti E
    Int J Biol Sci; 2024; 20(8):3173-3184. PubMed ID: 38904016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-associated SF3B1-K700E mutation controls immune responses by regulating T
    Shi Y; Zhang W; Jia Q; Zhong X; Iyer P; Wu H; Yuan YC; Zhao Y; Zhang L; Wang L; Jia Z; Kuo YH; Sun Z
    Sci Adv; 2024 Sep; 10(38):eado4274. PubMed ID: 39303038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The spliceosome as a target of novel antitumour drugs.
    Bonnal S; Vigevani L; Valcárcel J
    Nat Rev Drug Discov; 2012 Nov; 11(11):847-59. PubMed ID: 23123942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
    Yang JY; Huo YM; Yang MW; Shen Y; Liu DJ; Fu XL; Tao LY; He RZ; Zhang JF; Hua R; Jiang SH; Sun YW; Liu W
    Mol Oncol; 2021 Nov; 15(11):3076-3090. PubMed ID: 33932092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring
    Cheruiyot A; Li S; Nonavinkere Srivatsan S; Ahmed T; Chen Y; Lemacon DS; Li Y; Yang Z; Wadugu BA; Warner WA; Pruett-Miller SM; Obeng EA; Link DC; He D; Xiao F; Wang X; Bailis JM; Walter MJ; You Z
    Cancer Res; 2021 Sep; 81(17):4499-4513. PubMed ID: 34215620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
    Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
    Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-cancer analysis identifies mutations in
    Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
    Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.